Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 22;12(8):2012.
doi: 10.3390/cancers12082012.

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

María Rosario Chica-Parrado  1   2 , Ana Godoy-Ortiz  1   3 , Begoña Jiménez  1   3 , Nuria Ribelles  1   3 , Isabel Barragan  1   2   3   4 , Emilio Alba  1   2   3
Affiliations
Review

Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors

María Rosario Chica-Parrado et al. Cancers (Basel). .

Abstract

Neoadjuvant Chemotherapy (NAC) in Breast Cancer (BC) has proved useful for the reduction in tumor burden prior to surgery, allowing for a more extensive breast preservation and the eradication of subjacent micrometastases. However, the impact on prognosis is highly dependent on the establishment of Pathological Complete Response (pCR), in particular for Triple Negative (TN) and Hormonal Receptor negative/Human Epidermal growth factor Receptor 2 positive (HR-/HER2+) subtypes. Several pCR predictors, such as PAM50, Integrative Cluster (IntClust), mutations in PI3KCA, or the Trastuzumab Risk model (TRAR), are useful molecular tools for estimating response to treatment and are prognostic. Major evolution events during BC NAC that feature the Residual Disease (RD) are the loss of HR and HER2, which are prognostic of bad outcome, and stemness and immune depletion-related gene expression aberrations. This dynamic nature of the determinants of response to BC NAC, together with the extensive heterogeneity of BC, raises the need to discern the individual and subtype-specific determinants of resistance. Moreover, refining the current approaches for a comprehensive monitoring of tumor evolution during treatment, RD, and eventual recurrences is essential for identifying new actionable alterations and the integral best management of the disease.

Keywords: breast cancer; neoadjuvant chemotherapy; pathological complete response; predictive markers; residual disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Zaheed M., Wilcken N., Willson M.L., O’Connell D.L., Goodwin A. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst. Rev. 2019 doi: 10.1002/14651858.CD012873.pub2. - DOI - PMC - PubMed
    1. Kasimir-Bauer S., Bittner A.-K., König L., Reiter K., Keller T., Kimmig R., Hoffmann O. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 2016;18 doi: 10.1186/s13058-016-0679-3. - DOI - PMC - PubMed
    1. Penault-Llorca F., Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat. Rev. Clin. Oncol. 2016;13:487–503. doi: 10.1038/nrclinonc.2016.1. - DOI - PubMed
    1. Ogston K.N., Miller I.D., Payne S., Hutcheon A.W., Sarkar T.K., Smith I., Schofield A., Heys S.D. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast. 2003;12:320–327. doi: 10.1016/S0960-9776(03)00106-1. - DOI - PubMed
    1. Symmans W.F., Peintinger F., Hatzis C., Rajan R., Kuerer H., Valero V., Assad L., Poniecka A., Hennessy B., Green M., et al. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. J. Clin. Oncol. 2007;25:4414–4422. doi: 10.1200/JCO.2007.10.6823. - DOI - PubMed